{"title_page": "Sepsivac", "text_new": "'''Sepsivac''' is a novel drug developed by [[Cadila Pharmaceuticals]] to treat patients of [[gram-negative]] [[sepsis]] [[patients]]. \u00a0As an [[immunomodulatory]], it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by [[CSIR]] and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.<ref name=\":0\">{{Cite web|url=https://science.thewire.in/health/covid-19-csir-gram-negative-sepsis-sepsivac-clinical-trials/|title=Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus|last=Singh|first=Jyoti|date=2020-04-22|website=The Wire Science|language=en-GB|access-date=2020-04-28}}</ref>\n\n== Mechanism ==\nIn patients with sepsis, in response to an [[infection]], a lot of [[pro-inflammatory]] and [[anti-inflammatory]] [[cytokines]] are generated in the body. However, some of the cytokines also cause inflammation in the organs of the body, which might be harmful. [[Immunomodulator]] drugs such as Sepsivac regulate this host immune response.<ref>{{Cite news|last=Koshy|first=Jacob|url=https://www.thehindu.com/sci-tech/health/coronavirus-drug-for-sepsis-to-be-tested-for-covid-19/article31399594.ece|title=Coronavirus {{!}} Drug for sepsis to be tested for COVID-19|date=2020-04-21|work=The Hindu|access-date=2020-04-28|language=en-IN|issn=0971-751X}}</ref> Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.<ref>{{Cite web|url=https://www.indiaspend.com/gram-negative-sepsis-drug-to-be-trialled-for-treating-critically-ill-covid-19-patients/|title=Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients {{!}}|last=Paliath|first=Shreehari|date=2020-04-22|website=www.indiaspend.com|language=en-US|access-date=2020-04-28}}</ref>\n\n== Sepsivac and COVID-19 ==\nScientists at CSIR found similarities between the clinical characteristics of patients suffering from gram-negative sepsis and [[COVID-19]]. In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled [[clinical trial]] to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients.<ref name=\":0\" /> The repurposed drug will boost the immunity of the body and limit the spread of COVID-19 and increase the recovery rate.<ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/apr/24/sepsivac-to-be-tested-for-covid-19-treatment-2134537.html|title=Sepsivac to be tested for COVID-19 treatment|website=The New Indian Express|access-date=2020-04-28}}</ref> The clinical trials will be conducted at premier national hospitals like [[PGIMER Chandigarh]], [[AIIMS New Delhi]] and [[AIIMS]], Bhopal.<ref>{{Cite web|url=https://www.deccanherald.com/science-and-environment/50-yr-old-bacteria-drug-makes-a-comeback-in-fight-against-coronavirus-829105.html|title=50-yr-old bacteria drug makes a comeback in fight against coronavirus|date=2020-04-23|website=Deccan Herald|language=en|access-date=2020-04-28}}</ref>\n\n== References ==\n<references />\n\n{{INDEX}}\n\n[[Category:Sepsis]]\n[[Category:COVID-19]]\n[[Category:Research]]\n[[Category:Drugs]]\n[[Category:Medicine]]\n\n\n{{COVID-19-stub}}\n", "text_old": "\n\n'''Sepsivac''' is a novel drug developed by [[Cadila Pharmaceuticals]] to treat patients of [[gram-negative]] [[sepsis]] [[patients]]. \u00a0As an [[immunomodulatory]], it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by [[CSIR]] and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.<ref name=\":0\">{{Cite web|url=https://science.thewire.in/health/covid-19-csir-gram-negative-sepsis-sepsivac-clinical-trials/|title=Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus|last=Singh|first=Jyoti|date=2020-04-22|website=The Wire Science|language=en-GB|access-date=2020-04-28}}</ref>\n\n== Mechanism ==\nIn patients with sepsis, in response to an [[infection]], a lot of [[pro-inflammatory]] and [[anti-inflammatory]] [[cytokines]] are generated in the body. However, some of the cytokines also cause inflammation in the organs of the body, which might be harmful. [[Immunomodulator]] drugs such as Sepsivac regulate this host immune response.<ref>{{Cite news|last=Koshy|first=Jacob|url=https://www.thehindu.com/sci-tech/health/coronavirus-drug-for-sepsis-to-be-tested-for-covid-19/article31399594.ece|title=Coronavirus {{!}} Drug for sepsis to be tested for COVID-19|date=2020-04-21|work=The Hindu|access-date=2020-04-28|language=en-IN|issn=0971-751X}}</ref> Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.<ref>{{Cite web|url=https://www.indiaspend.com/gram-negative-sepsis-drug-to-be-trialled-for-treating-critically-ill-covid-19-patients/|title=Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients {{!}}|last=Paliath|first=Shreehari|date=2020-04-22|website=www.indiaspend.com|language=en-US|access-date=2020-04-28}}</ref>\n\n== Sepsivac and COVID-19 ==\nScientists at CSIR found similarities between the clinical characteristics of patients suffering from gram-negative sepsis and [[COVID-19]]. In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled [[clinical trial]] to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients.<ref name=\":0\" /> The repurposed drug will boost the immunity of the body and limit the spread of COVID-19 and increase the recovery rate.<ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/apr/24/sepsivac-to-be-tested-for-covid-19-treatment-2134537.html|title=Sepsivac to be tested for COVID-19 treatment|website=The New Indian Express|access-date=2020-04-28}}</ref> The clinical trials will be conducted at premier national hospitals like [[PGIMER Chandigarh]], [[AIIMS New Delhi]] and [[AIIMS]], Bhopal.<ref>{{Cite web|url=https://www.deccanherald.com/science-and-environment/50-yr-old-bacteria-drug-makes-a-comeback-in-fight-against-coronavirus-829105.html|title=50-yr-old bacteria drug makes a comeback in fight against coronavirus|date=2020-04-23|website=Deccan Herald|language=en|access-date=2020-04-28}}</ref>\n\n== References ==\n<references />\n\n[[Category:Sepsis]]\n[[Category: COVID-19]]\n[[Category: Research]]\n[[Category: Drugs]]\n[[Category: Medicine]]\n{{INDEX}}\n\n{{COVID-19-stub}}\n", "name_user": "Joeykai", "label": "safe", "comment": "clean up", "url_page": "//en.wikipedia.org/wiki/Sepsivac"}
